Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set away all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the company.

Irony of irony, my poor opinion of the business has grown steadily, however, the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of this know-how and also connected intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) and also the very first brand new drug program approval ($5 million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and numerous therapies, it has this individual therapy as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications and multiple presentations.

Can all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the really beginning of the interest of mine in this particular business. Judging by way of the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *